• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular
  • A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on top of low dose Acetyl Salicylic Acid(ASA) versus Clopidogrel on top of low dose ASA in Asian/Japanese Patients with Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for whom PCI is planned

Disease
acute coronary syndrome
Drug Name
Brilinta
Generic Name
Ticagrelor
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IIIb
Start Date
Feb 28, 2011
Study Name
D5130C00027
Study Id
D5130C00027
ClinicalTrials.gov ID
NCT01294462
Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013